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Abstract
Background: Pseudomonas aeruginosa typically displays loss of virulence-associated secretions over the course of
chronic cystic fibrosis infections. This has led to the suggestion that virulence is a costly attribute in chronic infections.
However, previous reports suggest that overproducing (OP) virulent pathotypes can coexist with non-producing mutants
in the CF lung for many years. The consequences of such within-patient phenotypic diversity for the success of this
pathogen are not fully understood. Here, we provide in-depth quantification of within-host variation in the production
of three virulence associated secretions in the Liverpool cystic fibrosis epidemic strain of P. aeruginosa, and investgate
the effect of this phenotypic variation on virulence in acute infections of an insect host model.
Results: Within-patient variation was present for all three secretions (pyoverdine, pyocyanin and LasA protease). In two
out of three patients sampled, OP isolates coexisted with under-producing mutants. In the third patient, all 39 isolates
were under-producers of all three secretions relative to the transmissible ancestor LESB58. Finally, this phenotypic
variation translated into variation in virulence in an insect host model.
Conclusions: Within population variation in the production of P. aeruginosa virulence-associated secretions can lead to
high virulence sub-populations persisting in patients with chronic CF infections.
Keywords: Pseudomonas aeruginosa, Liverpool epidemic strain, Public goods secretions, Virulence, Cystic fibrosis,
Pyoverdine, Pyocyanin, LasA protease
Background
Cystic fibrosis (CF) is an autosomal recessive genetic dis-
order that leads to thickened, viscous mucous obstructing
the airways, predisposing patients to lifelong bacterial lung
infections. The most prevalent pathogen causing such in-
fections is Pseudomonas aeruginosa, which is associated
with increased morbidity, a reduction in quality of life and
ultimately, mortality in CF patients [1]. Once established
in the CF lung, P. aeruginosa is often impossible to eradi-
cate [2], owing to high levels of antibiotic resistance and
rapid adaptation to a hostile and dynamic host environ-
ment [3, 4]. Over the course of chronic CF infections, P.
aeruginosa undergoes a series of genetic and phenotypic
changes in order to adapt to life within the host [5].
These typically include loss of virulence factors such
as the quorum-sensing regulated pyocyanin, elastase
and protease [6], the siderophore pyoverdine [6], as
well as emergence of hypermutators [3], conversion
to mucoidity [6, 7] increased antibiotic resistance [8]
and the loss of motility [6, 9].
Despite adaptation to the lung environment observed
in chronic P. aeruginosa CF infections, some highly
transmissible strains retain the ability to transmit to new
hosts and initiate new infections [10]. For instance, the
Liverpool Epidemic Strain (LES) is associated with en-
hanced morbidity [11], transmission among patients
[10], transmission to both non-CF parents of a CF pa-
tient [12], and a pet cat [13]. The LES is widespread
throughout UK CF clinics [14, 15] and is the most abun-
dant strain of P. aeruginosa in the UK CF population
[14]. Recently the LES has been reported in the sputa of
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CF patients in North America [16]. The ability of the
LES to maintain transmission, when adaptation to the
lung environment is likely to lead to loss of many of the
virulence-associated traits thought to be essential for es-
tablishing infections is paradoxical, and suggests that
more in-depth studies are required to gain a better
understanding of phenotypic variation in virulence-
associated secretions within the lung.
A growing number of recent studies have identified
substantial within-patient phenotypic diversity in P. aer-
uginosa expression of virulence factors, siderophores,
quorum sensing, antibiotic resistance, colony morph-
ology, motility and auxotrophy [17–22]. In the LES pop-
ulations, the phenotypic diversity among isolates within
a single CF lung sample is far greater than between sam-
ples from the same patient over time, and even between
patients [22]. Moreover, patients infected with the LES
typically harbour a mixture of OP phenotypes and
quorum sensing-defective lasR mutants [23]. The per-
sistence of OP phenotypes, in spite of the apparent cost
of virulence-associated secretions in chronic CF infec-
tions, suggests that these sub-populations may play an
important role in the transmissibility of the LES.
Here, we examine within-patient phenotypic diversity
in virulence-associated secretions for three CF patients
chronically infected with the highly transmissible LES
of P. aeruginosa for at least 2 years. To characterize
within-host variation in three virulence-associated se-
cretions: pyoverdine, pyocyanin and LasA protease, we
performed quantitative trait assays on 39 or 40 isolates
per patient and the earliest-known LES strain LESB58.
Furthermore, we show that within-host phenotypic
variation translates into variation in the virulence of
acute infections in an insect host model, indicating
that population diversity can act as a reservoir for
virulent pathotypes.
Results
Pyoverdine
Each patient harbored populations that, on average, pro-
duced less per capita pyoverdine relative to LESB58
(1-sample t-/wilcox test against 1; CF03:V = 129. 5, p <
0.001, CF08: t38 = 13.916, p < 0.001, CF10: V = 0, p < 0.001,
Fig. 1a). Patients CF03 and CF08 showed similar high
within-patient variance in pyoverdine production (CF03
range: 4–116%; CF08 range: 8–113%), driven by the coex-
istence of isolates that produced pyoverdine at levels at
least as high as LESB58, with isolates that produced less
than 10% relative to LESB58. In contrast, pyoverdine pro-
duction in patient CF10 was greatly reduced and far less
variable among isolates compared to CF03 and CF08, with
all isolates producing less than 50% of LESB58’s pyover-
dine (CF10 range: 6–47%).
Pyocyanin
Patients CF03 and CF08 harboured P. aeruginosa popu-
lations that produced elevated levels of mean per capita
pyocyanin relative to LESB58 (1-sample t- /wilcox test
against 1; CF03: V = 573, p < 0.05, CF08: t38 = 5.6253, p <
0.001, Fig. 1b). However, per capita pyocyanin produc-
tion among isolates displayed high variance within both
patients, ranging from 7 to 266% LESB58 levels in CF03,
and from 15 to 300% in CF08. In both populations, iso-
lates that produced <20% of the pyocyanin produced by
LESB58, coexisted with pyocyanin OP’s (200–300% of
LESB58 levels). By contrast, isolates from patient CF10
displayed lower mean per capita pyocyanin relative to
LESB58 (1-sample Wilcox test against 1; CF10: V = 0,
p < 0.001, Fig. 1b). Within-population variation in
CF10 was much lower than that observed in CF08 or
CF03, with pyocyanin production ranging from 14 to
80% that of LESB58 levels.
LasA protease
Each patient harbored populations that produced signifi-
cantly lower mean per capita protease relative to
LESB58 (1-sample t- /wilcox test against 1; CF03: V = 0,
p < 0.001, CF08: V = 101, p < 0.001, CF10: t38 = 228.18, p
< 0.001, Fig. 1c). Patients CF03 and CF08 showed similar
high within-host variation in per capita protease produc-
tion (CF03 range: 0–80%; CF08 range: 10–119%), while
isolates from patient CF10 showed much reduced levels
of protease relative to LESB58, between just 6–16%. In
patients CF03 and CF08, therefore, LasA protease under-
producers coexisted with isolates producing 80–120% of
LESB58 levels, whereas isolates from patient CF10 were
all LasA protease underproducers.
Correlations between different secretions
We performed principal component analysis on all
118 isolates to investigate associations among produc-
tion of these secretions. Overall, isolates typically ei-
ther upregulated all three secretions, or produced
very little of any (PC1 explains 73% variance, Add-
itional file 1: Figure S1). While PC1 predicts that all
three secretions are positively correlated, pyocyanin
and LasA protease show the strongest association.
We confirmed this by performing linear mixed effects
models (with patient ID as a random variable), which
confirmed that the strongest positive correlation was
between pyocyanin and protease production (X23 =
90.761, p < 0.0001, Fig. 2) followed by pyocyanin and
pyoverdine (X23 = 29.908, p < 0.0001) and finally pyo-
verdine and protease (X23 = 19.307, p < 0.0001).
We next performed the same analysis independently
for each patient (CF03, CF08 and CF10). Isolates from
CF03 and CF08 were consistent with findings using the
full dataset: all three secretions were positively
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correlated, with the strongest association between LasA
protease and pyocyanin (PC1, CF03: 76.3% variance,
Additional file 2: Figure S2; CF08: 65.1% variance, Add-
itional file 3: Figure S3). However isolates from patient
CF10 showed a negative correlation between pyocyanin
and pyoverdine, so that downregulating pyoverdine was
associated with elevated production of pyocyanin (PC1,
62.7% variance, Additional file 4: Figure S4).
Virulence assays
To assess whether within-patient diversity could act
as a resevoir for virulent pathotypes, we performed
virulence assays using 40 isolates from the population
with the highest phenotypic diversity, CF03, as well as
the ancestral strain LESB58. Isolates varied in their
ability to form virulent infections in a waxmoth host
model, ranging from host death within 1 h of
Fig. 2 While all three secretions were, overall, positively correlated, we find the strongest relationship between pyocyanin and LasA protease production
(both regulated by LasR) (X23 = 90.761, p< 0.0001). Each datapoint represents a single isolate, n= 118
Fig. 1 a Per capita pyoverdine (b) pyocyanin and c LasA protease production relative to that of LESB58 for each patient (CF03, CF08 and CF10).
a Mean pyoverdine production is reduced in each patient relative to LESB58 (CF03: V = 129. 5, p < 0.001, CF08: t38 = 13.916, p < 0.001, CF10: V = 0,
p < 0.001), b Mean pyocyanin production is increased relative to LESB58 in patients CF03 and CF08 (CF03: V = 573, p< 0.05, CF08: t38 = 5.6253, p< 0.001),
but reduced in CF10 (V = 0, p< 0.001), c Mean LasA protease is reduced in each patient relative to LESB58 (CF03: V = 0, p< 0.001, CF08: V = 101, p< 0.001,
CF10: t38 = 228.18, p< 0.001). When y= 1, production of the relevant secretion does not differ to that of LESB58. Datapoints represent each of 40 isolates
for CF03, 39 for CF08 and 39 for CF10
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innoculation to completely avirulent infections (no
survival difference between infected and control lar-
vae); by comparison, LESB58 killed their waxmoth
hosts within an average of 15 h post infection. Rapid
mortality of waxmoth hosts was positively associated
with pyoverdine production (X21 = 19.18, p = 0.00001)
and, less strongly, with pyocyanin production (X21 =
10.072, p = 0.0002), but we found no statistically sig-
nificant association between protease production and
mortality rate (X21 = 1.18143, p > 0.1). Note, however,
that pyocyanin and protease production were highly
positively correlated in this population, as we have
shown above. Hence, on removing the confounding
effect of pyocyanin from the full model, protease be-
came an important predictor of waxmoth mortality (X21
= 9.2294, p = 0.002).
Lineage specific virulence
Williams et al. [24] analysed the phylogenetic relation-
ship between the 40 P. aeruginosa isolates from patient
CF03 based on whole genome sequences for each isolate.
This population comprises of two LES lineages, A and B.
Lineage A is characterised by a non-synonymous muta-
tion in the lasR gene, and so we hypothesised that the
production of pyocyanin and protease (which are LasR
dependent), and to a lesser extent, pyoverdine (which is
upregulated by, but not dependent on LasR) would show
an association with lineage. Production of all three se-
cretions was higher for isolates in lineage B compared
with lineage A (glm secretion ~ lineage; pyoverdine: F1,38
= 18.554, p = 0.0001, pyocyanin: F1,38 = 50.008, p < 0.0001,
protease: F1,38 = 188.12, p < 0.0001, Fig. 3). Accordingly,
waxmoths infected with isolates from lineage B (with in-
tact lasR) were killed 3 times faster than those infected
with isolates from lineage A (z = 6.39, p < 0.0001).
Discussion
The secretion of virulence-factors by P. aeruginosa is
thought to be associated with the establishment of infec-
tion in CF. The current paradigm is that if these acute
infections become chronic, virulence-associated secre-
tions become less beneficial or costly, and are lost via
the accumulation of mutations, particularly in global
regulators (e.g. lasR) [6, 25]. By quantifying the produc-
tion of three virulence-associated secretions (pyocyanin,
LasA protease and pyoverdine) for 118 P. aeruginosa
isolates from three CF patients, we show that the loss of
virulence-associated secretions is not always universal
within patients. We report that in two out of three pa-
tients, isolates that secreted very little (underproducers),
coexisted with isolates that produced secretions at levels
at least as high, or several fold higher (overproducers),
than the earliest-known LES strain LESB58. Moreover,
we show that this diversity has consequences for viru-
lence: overproducing isolates displayed higher virulence
in a waxmoth larval host, suggesting that within popula-
tion diversity acts as a ‘resevoir’ for high-virulence sub-
populations even in long-term chronic infections. Hence,
while the general paradigm is that population-level pro-
duction of virulence-associated secretions decline during
chronic infection [6, 25], this does not imply that the
ability to cause virulent infections is completely lost. In
light of this, effectively diagnosing P. aeruginosa CF in-
fections strongly depends on in-depth microbiological
screening that takes into account within-patient
diversity.
Our study reveals that overall, within-host P. aerugi-
nosa isolates exhibit reduced population-level produc-
tion of pyoverdine and LasA protease relative to
LESB58. Since we sacrifice sampling at the patient level
at the expense of more in-depth analysis of within-
patient diversity, we cannot make any firm claims about
Fig. 3 Per capita production of (a) pyoverdine, b pyocyanin and c LasA protease relative to LESB58 for patient CF03 only. Secretions were higher
for isolates in lineage B compared with lineage A (glm secretion ~ lineage; pyoverdine: F1,38 = 18.554, p = 0.0001, pyocyanin: F1,38 = 50.008, p < 0.0001,
protease: F1,38 = 188.12, p < 0.0001). Information on lineages was obtainined from Williams et al. [24]. Each datapoint represents one of 40 isolates
originating from patient CF03. When y = 1, production of the relevant secretion does not differ to that of LESB58
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whether this finding is representative of P. aeruginosa
chronic infections in general. However, our findings are
consistent with previous studies that sample fewer iso-
lates from a larger number of patients, such as Andersen
et al. [26] (13 isolates/ patient sample) and Hoffman et
al. [27] (2.8 isolates/ patient sample). Our results also re-
veal differences between populations. Notably, while in-
fections within patients CF03 and CF08 demonstrated
high within-population diversity, whereby over- and
under-producing isolates coexisted, isolates from patient
CF10 tended to produce very little, if any, of the three
secretions that we quantified. This finding is supported
by previous work that investigated the phylogenetic rela-
tionship between isolates within these three patients,
showing that while CF03 and CF08 populations consist
of two genetically diverged lineages, the CF10 population
consists of just one [24]. Our finding that patient CF10
harboured less phenotypic diversity than CF03 and CF08
may be partially explained by duration of infection. At
the time of sampling, patient CF10 had been infected
with P. aeruginosa for the least amount of time (2 years),
compared with CF03 (3 years) and CF08 (>5 years) [22].
However, our finding that CF03 and CF08 show similar
levels of diversity, when CF03 and CF10 have been in-
fected for more similar periods of time suggests that
duration of infection is not the only predictor of pheno-
typic diversity.
This study, along with several others [23, 28] suggests
that OP phenotypes are commonly found in combin-
ation with underproducers within the CF lung. While
the explanation for the maintenance of OP phenotypes
in chronic infections remains to be elucidated, this study
provides a potential explanation: OP phenotypes may re-
tain the ability to transmit between patients, and levels
of secreted virulence-factor production may therefore
represent a trade-off between adaptation to either a
chronic or acute infection lifestyle. However, evolution
has no foresight and so it would be difficult to see how
maintaining virulence in a chronic context would be
favoured, even if a new infection could be better initi-
ated in the future. Hence, while highly virulent subpopu-
lations may be beneficial for transmission, it is likely that
other factors play a role in shaping virulence in chronic
infections. One possibility is that secretions that confer a
benefit to nearby conspecifics will be lost from a popula-
tion, because non-producing conspecifics can still access
the benefits without paying the cost of making the secre-
tion. Hence, non-producing ‘cheats’ invade populations
of ‘cooperative’ producers [26]. Moreover, recent in vitro
work has shown that coevolution between P. aeruginosa
cooperators and cheats enables them to coexist, because
cooperators become more difficult to exploit, and cheats
become more efficient exploiters [29]. While the exploit-
ation of virulence-associated secretions by non-producers
could explain the emergence of non-producing LasR mu-
tants in the context of CF, this has yet to be experimen-
tally investigated.
Understanding the bacterial characteristics that con-
tribute most to disease is a major path toward develop-
ing novel “disarming” antimicrobials [30]. A handful of
previous studies have monitored the ability of phenotyp-
ically varied LES isolates to form acute infections. In a
mouse model of acute infections, Carter et al. [31] re-
vealed subtle variation in four LES subtypes (including
LESB58) in their ability to kill their host. LES431, (asso-
ciated with reduced biofilm, and elevated pyocyanin,
elastase and protease production) was best at forming
acute infections in a mouse model whereas all mice in-
fected with the quorum-sensing-negative lasR mutant
LES400 survived the entire duration of the experiment.
While this might suggest that quorum-sensing is import-
ant for establishing acute infection in mice, all LESB58
(with an intact lasR system) infected mice also survived.
Similar results were observed in fruit flies: LES431 and
LES400 formed the most and least virulent infections,
respectively, out of seven LES strains from different
sources of infection [32]. Our study reveals that the pro-
duction of pyoverdine, pyocyanin and LasA protease are
all important predictors of virulence in a waxmoth larva
host. While these secretions were highly correlated, pyo-
verdine emerged as the greatest contributor to virulence.
A recent meta-analysis has shown that in lab strains
such as PAO1 and PA14, the effect of pyoverdine, albeit
frequently contributing to disease, is relatively minor,
and varies considerably across infection models [33].
While these strains were initially isolated from clinical
settings, they have subsequently undergone evolution in
the laboratory environment [34], and hence may differ
substantially from the clinical strains used in this study.
Hence, the role of pyoverdine may be more prominent
in studies such as this one that use clinical populations
comprising of OP strains and lasR mutants. Our results
suggest that to fully understand the ability of virulence-
associated secretions to reduce host health and survival,
it is vital to carry out additional studies on diverse clin-
ical isolates. This approach is especially relevant for de-
veloping novel therapeutics that curb P. aeruginosa
pathogenicity by targeting a specific virulence-associated
secretion.
Conclusion
Isolates of a CF epidemic strain of P. aeruginosa have
been previously shown to display a) loss of viurlence-
encoding genes over the course of infection and b)
considerable within-patient phenotypic diversity. We
demonstrate that this diversity in virulence-associated
secretions among isolates means that OP virulent strains
can sometimes be present in combination with non-virulent
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strains. Hence, despite the common loss of virulence as P.
aeruginosa adapts to the CF lung environment, the persist-
ence of high-virulence subpopulations may allow high rates
of transmission among patients to be retained.
Methods
Patients and samples
Routine sputum samples from CF patients harboring
long-term LES infections were collected from 10 pa-
tients between January 2009 and May 2011 [22, 28].
Briefly, ~40 colonies were isolated per sample, ensuring
that each different colony morphology type was propor-
tionally represented. Each isolate was confirmed as P.
aeruginosa LES, using polymerase chain reaction assays.
For this study, we focused on patients CF03, CF08 and
CF10, because they were best matched in terms of pa-
tient characteristics (all female, aged between 20 and 25,
FEV1 = 36–37%). A single sputum sample from each pa-
tient, collected in January 2009, was selected for our
experimental investigations (CF03 (Stable_2); CF08
(Stable_1); CF10 (Stable_1), as detailed in [22]). All sam-
ples used were isolated during routine visits to the clinic
(i.e. lung condition was relatively stable). Population
genetic structure for each sample is detailed in Williams
et al. (2015), revealing that two of our samples (CF08
and CF08) comprise of two lineages, while CF10 consists
of a single lineage. Due to difficulties in culturing some
isolates, our dataset comprised of 40 isolates from CF03,
39 isolates from CF08 and 39 isolates from CF10. As a
comparison we used LESB58 [35], the earliest archived
LES isolate.
Pyoverdine measurements
We quantified per capita production of the most costly
and efficient iron-chelating siderophore, pyoverdine
[36–38] using a pyoverdine specific exitation-emmission
assay [38–41]. 118 CF isolates, and LESB58 were cul-
tured in 6 ml Lysogeny broth (LB) for 24 h at 37 °C,
shaken at 180 rpm. The optical density (OD; A600)
was measured at 600 nm and standardized to 1
(~109 CFU ml−1) using M9 buffer. 107 cells were then
added to 200 μl Casamino acid (CAA) medium in 96
well-plates, made iron-limited by the addition of freshly
made filter-sterilised 100 μg/ml human apotransferrin
and 20 mM NaHCO3 immediately before use. Since sid-
erophore production is repressed when there is an ex-
cess of Fe2+ [42, 43], iron-limitation ensures that
siderophores are essential for growth and stimulates
their production. Outer wells were filled with 200 μl
CAA media only to minimise evaporation. Plates were
grown static at 37 °C for 24 h. Cultures were then di-
luted ×10 with ddH20 and fluorescence of each culture
was measured at 460 nm following excitation at 400 nm,
using a Tecan infinite M200 pro spectrophotometer. OD
was measured at 600 nm, and the ratio fluorescence/OD
was employed as a quantitative measure of per capita
pyoverdine production [44, 45].
Pyocyanin measurements
Per capita pyocyanin production was determied for each
CF isolate and LESB58. Isolates were cultured in 6 ml
LB broth for 24 h at 37 °C, shaken at 180 rpm. OD was
standardized to 1 (~109 CFU ml−1), using M9 buffer. 107
cells were then innoculated into 6 ml LB broth, and
grown at 37 °C for 24 h shaken at 180 rpm. 1 ml of each
culture was centrifuged at 18,000 g for 3 minutes. Per
capita pyocyanin production was measured for each iso-
late by measuring A691 of the supernatant, and then
standardizing by bacterial OD [46].
LasA protease measurements
LasA protease activity was quantified by determining the
ability of P. aeruginosa culture supernatants to lyse
boiled Staphyloccous aureus cells [47]. Briefly, a 20 ml
volume of overnight S. aureus cells was boiled for
10 min in a waterbath, and then centrifuged for 10 min
at 10,000 rpm. The resulting pellet was resuspended in
0.02 M aTris-HCl (ph 8.5) to an OD of ~ 0.9. Each bac-
terial isolate was cultured in 6 ml LB broth for 24 h at
37 °C, shaken at 180 rpm, and OD standardized to 1
(~109 CFU ml−1) using M9 buffer. 107 cells were then
added to a further 6mls LB broth, and grown at 37 °C
for 24 h shaken at 180 rpm. Supernatant was obtained
by centrifuging 1 ml at 18,000 g for 3 min. 7.5 μl of each
LES supernatant was mixed with 142.5 μl S. aureus cells
and OD was measured at time 0 and again after 60 min.
This assay was replicated three times for each isolate.
Per capita LasA protease activity was quantified by div-
iding the reduction in OD for each isolate by the OD of
each starting population.
In vivo virulence assays
In order to investigate whether phenotypic diversity
could translate into virulence diversity, we performed a
survival analysis using 40 isolates from patient CF03
only. This patient was chosen because 1) these isolates
all have complete genome sequences available, so sur-
vival data would be a valuable asset to this dataset and
2) CF03 exhibited a high amount of within-host variation.
Forty isolates from CF03, and LESB58 were cultured in
6 ml LB broth for 24 h at 37 °C, shaken at 180 rpm. OD
was standardized to 0.1 (~108 CFU ml−1), using sterile
NaCl (80% w/v). Larvae were purchased the day prior to
inoculation from Pets at Home, York, UK. Larvae were
swabbed with 70% v/v ethanol to prevent contamination
of the injection site, and diluted isolates were injected in
the abdomen using a Hamilton syringe. The injection vol-
ume was 7 μl in all cases (~106 cells). Six larvae were
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assigned to each of 41 treatments (40 LES isolates from
CF03 and LESB58). A further 6 larvae were injected with
7 μl 80% NaCl as negative controls; their mortality rate
was null. Larvae were incubated at 37 °C and monitored
for death at hourly intervals between 0 and 24 h post-
inoculation. Larvae were scored as dead if they failed to
respond to mechanical stimulation of the head.
Statistical analysis
All measurements were standardised by bacterial density
to obtain per capita values.
Assay measurements were divided by the relevant
LESB58 value, to determine the change in their produc-
tion relative to the ancestor. When this value =1 evolved
isolates and LESB58 did not differ in quantity of secreted
product. To assess differences we performed one-sample
t-tests/wilcox tests against 1. General linear models were
employed to assess whether lineage predicted levels of
production of each secretion in patient CF03. We used
three linear mixed effects models, to verify the relation-
ship between pyocyanin and pyoverdine, pyocyanin and
LasA protease, and pyoverdine and lasA protease,
assigning “patient” as a random effect. Survival analysis
was performed using a cox proportional hazards model
with three continuous variables (pyocyanin, pyoverdine
and protease) as the response variable, including 3- way
and 2-way interactions. All data were analysed using R
version 2.15.1 [48].
Additional files
Additional file 1: Figure S1. Results of principal component analysis
whereby all 188 isolates were pooled to investigate associations among
production of these secretions. Overall, isolates typically either upregulated all
three secretions, or produced very little of any (PC1 explains 73% variance).
(GIF 368 kb)
Additional file 2: Figure S2. Results of principal component analysis
using phenotypic measurements from 40 isolates originating from patient
CF03, showing that all three secretions were positively correlated, with the
strongest association between LasA protease and pyocyanin (PC1, 76.3%
variance). (GIF 194 kb)
Additional file 3: Figure S3. Results of principal component analysis
using phenotypic measurements from 39 isolates originating from patient
CF08, showing that all three secretions were positively correlated, with the
strongest association between LasA protease and pyocyanin (PC1, 65.1%
variance). (GIF 212 kb)
Additional file 4: Figure S4. Results of principal component analysis
using phenotypic measurements from 39 isolates originating from patient
CF10, revealing a negative correlation between pyocyanin and pyoverdine
(PC1, 62.7% variance). (GIF 79 kb)
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